Co-payments have been linked to the slowing growth in pharmaceutical spending over the last five years. However, patients with health problems frequently have difficulty affording their pharmacotherapy and fail to take their medication as prescribed. We examine the relationship between co-payment amounts and four types of cost-related underuse: taking fewer doses, postponing taking a medication, failing to fill a prescription at all, and taking medication less frequently than prescribed. We conducted a nationwide survey of US adults age 50 and over who take medication for a chronic condition. Participants provided information on 17 chronic conditions, medication they take for those conditions, and whether they underused any medication due to cost. We analyzed those who reported paying co-payments for their prescriptions (n = 2,869). Analysis involved multivariate logistic regression, with adjustments for survey weights and clustering. Our data show a strong positive association between co-payments and cost-related medication underuse. Although people differ in how they underuse medications, these behaviours are strongly associated with co-payment amount. Realigning the co-payments with cost-effectiveness data, also known as value-based insurance design, warrants further investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1744133107004380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice.
Curr Cardiol Rep
October 2021
Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, 375 Longwood Ave, 4th Floor, Boston, MA, 02215, USA.
Purpose Of Review: The launch of new effective and safe cardiovascular drugs has produced large gains in health outcomes for several cardiovascular conditions. But this innovation comes at the cost of rapidly increasing pharmaceutical spending and high out-of-pocket costs.
Recent Findings: In the USA, manufacturers are able to set prices according to what the market will bear rather than value to patients or society, with a complicated system of discounts and rebates obscuring the final price borne by payors.
The Effect Of Veterans Health Administration Coverage On Cost-Related Medication Nonadherence.
Health Aff (Millwood)
January 2020
Danny McCormick is an associate professor of medicine at Harvard Medical School and director of the Division of Social and Community Medicine in the Department of Medicine, Cambridge Health Alliance.
High out-of-pocket drug spending worsens adherence and outcomes, especially for patients who are poor, chronically ill, or members of minority groups. The Veterans Health Administration (VHA) system provides drugs at minimal cost, which could reduce cost-related medication nonadherence. Using data for 2013-17 from the National Health Interview Survey, we evaluated the association of VHA coverage with such nonadherence.
View Article and Find Full Text PDFStatewide Assessment of Cost-Related Healthcare Access Barriers in Rhode Island.
R I Med J (2013)
November 2016
Director of Health, State of Rhode Island.
Although co-payments and deductibles are means of keeping health expenditures low, they have also been cited as barriers that inhibit patients from accessing necessary healthcare. We aimed to evaluate Rhode Island residents' experiences with cost-related access challenges within the state's healthcare system. We conducted a cross-sectional survey of resident experiences with healthcare in Rhode Island.
View Article and Find Full Text PDFDeterminants of Cost-Related Nonadherence to Medications among Chronically Ill Patients in Maccabi Healthcare Services, Israel.
Value Health Reg Issues
September 2014
Department of Health Systems Management, Guilford Glazer Faculty of Business and Management and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Background: The effectiveness of value-based insurance design is based on nonadherence, which derives solely from patients' economic constraints.
Objective: Our objective was to examine the extent of cost-related nonadherence to chronic medications and to analyze its potential determinants.
Methods: We conducted a telephone survey among a representative sample of Maccabi Healthcare Services chronically ill patients aged 55 years or older (n = 522).
Patient-centered outcomes of a value-based insurance design program for patients with diabetes.
Popul Health Manag
April 2013
Christiana Care Health System, Newark, Delaware 19718, USA.
Value-based insurance design (VBID) initiatives have been associated with modest improvements in adherence based on evaluations of administrative claims data. The objective of this prospective cohort study was to report the patient-centered outcomes of a VBID program that eliminated co-payments for diabetes-related medications and supplies for employees and dependents with diabetes at a large health system. The authors compared self-reported values of medication adherence, cost-related nonadherence, health status, and out-of-pocket health care costs for patients before and 1 year after program implementation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!